In conclusion, our findings highlight the potential for targeting VIP signaling and ILC3 as a novel therapeutic strategy to ameliorate hepatic steatosis and highlight the need to further understand how neuroimmune modulation can affect metabolic disorders, including MASLD. Here, VIP is linked to Other metabolic disease.